Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Rejects Repros Hypogonadism Drug; Shares Tumble

This article was originally published in Scrip

Executive Summary

The FDA slapped Repros Therapeutics Inc. with a complete response letter (CRL), rejecting the company's new drug application (NDA) for enclomiphene, formerly known as Androxal, as a treatment for secondary hypogonadism in overweight men seeking to restore normal testicular function.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register